top of page

4N8A1902

Purchased Photo - myeloid cells and CD4+

Dr Sabelo (Picture: Métro Journal)

4N8A1902
1/10
CanCURE
The Canadian HIV Cure Enterprise (CanCURE) is a research collaboratory focused on studying HIV persistence during antiretroviral therapy and developing strategies towards a sustainable HIV remission. Our innovative scientific program is supported by the Canadian Institutes of Health Research (CIHR).
CanCURE Photo Gallery

4N8A1981

4N8A1975
CanCURE AGM 2019 - Group Photo

4N8A1954
CanCURE 2019 Key Note Speaker

4N8A1902

CanCURE AGM 2019
CanCURE AGM 2019 Public Session

CanCURE AGM 2019
CanCURE AGM 2019 Poster Session

CanCURE AGM 2019
CanCURE AGM 2019 Poster Session

CanCURE AGM 2019
CanCURE AGM 2019 Poster Session

CanCURE AGM 2019

CanCURE Annual General Meeting 2017
Dr. Brendan Bell Presenting at AGM, Oct 19th, 2017, IRCM, Montreal

2017 CanCURE Group picture
Annual General Meeting, Oct 19-20th, 2017, IRCM, Montreal

AGM2017 Poster Prizes Recipients
From left to right: Tomas Raul Wiche Salinas (Centre hospitalier de l’Université de Montréal Research Center, CRCHUM), Marta Massanella (CRCHUM), Éric A Cohen (IRCM), Segen Kidane (University of Toronto), Dr. Alan Cochrane (University of Toronto), Dr. Petronela Ancuta (CRCHUM), and Dr. Nicolas Chomont (CRCHUM).

Dr Mujib
University of Toronto, 2017


Community liaison picture, 2016
1/2
​
Available Positions
Research Assistant or Associate
Available at the Research Institute of McGill University Health Centre (RI-MUHC) to work on CIHR-funded research studies on HIV immunology. The candidate will be supervised by Dr Cecilia Costiniuk, Associate Professor in Infectious Diseases at McGill.
​
Postdoctoral Fellow
Available at the Research Institute of McGill University Health Centre (RI-MUHC) to work on CIHR-funded research studies on HIV immunology. The candidate will be supervised by Dr Cecilia Costiniuk, Associate Professor in Infectious Diseases at McGill.
Postdoctoral Fellow
Human Immunodeficiency Virus (HIV)-host interactions governing HIV persistence in different models of humanized mice. Dr. Eric Cohen, Montreal Clinical Research Institute (IRCM, Montreal)
Publications
​
Clain et al. Early ART reduces viral seeding and innate immunity in liver and lungs of SIV-infected macaques. JCI insight. July 2023
Gantner et al. HIV rapidly targets a diverse pool of CD4+ T cells to
establish productive and latent infections. Immunity. March 2023
​
Colas et al. Generation of functional human T cell development in NOD/SCID/IL2rγnull humanized mice without using fetal tissue: Application as a model of HIV infection and persistence. Stem Cell Reports. February 2023
​
Fert et al. Targeting Th17 cells in HIV-1 remission / cure interventions. Trends in Immunology. July 2022
​
Tremblay et al. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in
Human Primary Macrophages. Journal of Virology. February 2022
​
Murooka et al. T cell migration potentiates HIV infection by
enhancing viral fusion and integration. Cell Reports. February 2022
​
Salinas et al. Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. PNAS. November 2021
​
Planas et al. Peculiar Phenotypic and Cytotoxic Features of Pulmonary Mucosal CD8 T Cells in People Living with HIV Receiving Long-Term Antiretroviral Therapy. EBioMedicine. March 2021​​
​
Routy et al. Beyond the Absence of CD4 T-Cell Count: A Novel Genetic CD4 T-Cell Deficiency Disorder With a Contingency Plan. J Infect Dis. February 2021
​
Peng et al. Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis. J Virus Erad.​ February 2021
​
Abdel-Mohsen et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Med. September 2020
​
Gantner et al. Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. Nature Communications. August 2020
bottom of page